In the US, Adalimumab (adalimumab systemic) is a member of the following drug classes: antirheumatics, TNF alfa inhibitors and is used to treat Ankylosing Spondylitis, Behcet's Disease, Crohn's Disease, Crohn's Disease - Acute, Crohn's Disease - Maintenance, Hidradenitis Suppurativa, Juvenile Idiopathic Arthritis, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Reiter's Syndrome, Rheumatoid Arthritis, Spondyloarthritis and Ulcerative Colitis.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
Disease-modifying antirheumatic drug, DMARD
Tumor necrosis factor alpha (TNF-α) inhibitor
Immunoglobulin G 1 (human monoclonal D2E7 heavy chain anti-human tumor necrosis factor), disulfide with human monoclonal D2E7κ-chain, dimer (WHO )
- Adalimumabum (Latin)
- Adalimumab (German)
- Adalimumab (French)
- Adalimumab (Spanish)
- Adalimumab (OS: BAN, USAN)
- Adalimumab (Genetical Recombination) (OS: JAN)
- D 2E7 (IS)
- LU 200134 (IS)
Abbott, Argentina; Abbott, Bosnia & Herzegowina; Abbott, Belgium; Abbott, Chile; Abbott, China; Abbott, Colombia; Abbott, Czech Republic; Abbott, Ecuador; Abbott, Egypt; Abbott, Spain; Abbott, Finland; Abbott, Hong Kong; Abbott, Croatia (Hrvatska); Abbott, Ireland; Abbott, Italy; Abbott, South Korea; Abbott, Mexico; Abbott, Oman; Abbott, Peru; Abbott, Portugal; Abbott, Romania; Abbott, Serbia; Abbott, Singapore; Abbott, Slovenia; Abbott, Slovakia; Abbott, Tunisia; Abbott, Taiwan; Abbott, United States; Abbott, Venezuela; Abbott, South Africa; Abbott Laboratories, Lithuania; AbbVie, Austria; AbbVie, Australia; AbbVie, Canada; AbbVie, Switzerland; AbbVie, Germany; AbbVie, Denmark; AbbVie, United Kingdom; AbbVie, Greece; AbbVie, Hungary; AbbVie, Japan; AbbVie, Latvia; AbbVie, Netherlands; AbbVie, Norway; AbbVie, New Zealand; AbbVie, Sweden; AbbVie, Turkey; AbbVie A/S, Iceland; ABBVIE BIOPHARMACEUTICALS, Israel; AbbVieAbbVie Limited, France; Vetter Pharma, Lebanon
- Humira (pediatric)
AbbVie, United Kingdom
- Humira Kinder (pediatric)
|BAN||British Approved Name|
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Click for further information on drug naming conventions and International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.